-
Mashup Score: 348Immune-Related Adverse Events of Immune Checkpoint Inhibitors | Annals of Internal Medicine - 1 month(s) ago
Immune-related adverse events (irAEs) are toxicities that arise after the administration of monoclonal antibodies targeting immune checkpoints (immune checkpoint inhibitors [ICIs]) in patients with cancer. They can occur at any time after initiation of ICI treatment, with a broad clinical phenotype that can be organ-specific or systemic. Although most irAEs manifest as mild to moderate signs and symptoms, severe forms of irAEs can lead to irreversible organ failure and have acute life-threatening presentations. Treatment should be tailored to the specific organ involved and the severity. Glucocorticoids are the first-line treatment for most irAEs, with immunosuppressants and biologics mainly used as second-line treatments.
Source: www.acpjournals.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 345Immune-Related Adverse Events of Immune Checkpoint Inhibitors | Annals of Internal Medicine - 2 month(s) ago
Immune-related adverse events (irAEs) are toxicities that arise after the administration of monoclonal antibodies targeting immune checkpoints (immune checkpoint inhibitors [ICIs]) in patients with cancer. They can occur at any time after initiation of ICI treatment, with a broad clinical phenotype that can be organ-specific or systemic. Although most irAEs manifest as mild to moderate signs and symptoms, severe forms of irAEs can lead to irreversible organ failure and have acute life-threatening presentations. Treatment should be tailored to the specific organ involved and the severity. Glucocorticoids are the first-line treatment for most irAEs, with immunosuppressants and biologics mainly used as second-line treatments.
Source: www.acpjournals.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 344Immune-Related Adverse Events of Immune Checkpoint Inhibitors | Annals of Internal Medicine - 2 month(s) ago
Immune-related adverse events (irAEs) are toxicities that arise after the administration of monoclonal antibodies targeting immune checkpoints (immune checkpoint inhibitors [ICIs]) in patients with cancer. They can occur at any time after initiation of ICI treatment, with a broad clinical phenotype that can be organ-specific or systemic. Although most irAEs manifest as mild to moderate signs and symptoms, severe forms of irAEs can lead to irreversible organ failure and have acute life-threatening presentations. Treatment should be tailored to the specific organ involved and the severity. Glucocorticoids are the first-line treatment for most irAEs, with immunosuppressants and biologics mainly used as second-line treatments.
Source: www.acpjournals.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 344Immune-Related Adverse Events of Immune Checkpoint Inhibitors | Annals of Internal Medicine - 2 month(s) ago
Immune-related adverse events (irAEs) are toxicities that arise after the administration of monoclonal antibodies targeting immune checkpoints (immune checkpoint inhibitors [ICIs]) in patients with cancer. They can occur at any time after initiation of ICI treatment, with a broad clinical phenotype that can be organ-specific or systemic. Although most irAEs manifest as mild to moderate signs and symptoms, severe forms of irAEs can lead to irreversible organ failure and have acute life-threatening presentations. Treatment should be tailored to the specific organ involved and the severity. Glucocorticoids are the first-line treatment for most irAEs, with immunosuppressants and biologics mainly used as second-line treatments.
Source: www.acpjournals.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 334Immune-Related Adverse Events of Immune Checkpoint Inhibitors | Annals of Internal Medicine - 3 month(s) ago
Immune-related adverse events (irAEs) are toxicities that arise after the administration of monoclonal antibodies targeting immune checkpoints (immune checkpoint inhibitors [ICIs]) in patients with cancer. They can occur at any time after initiation of ICI treatment, with a broad clinical phenotype that can be organ-specific or systemic. Although most irAEs manifest as mild to moderate signs and symptoms, severe forms of irAEs can lead to irreversible organ failure and have acute life-threatening presentations. Treatment should be tailored to the specific organ involved and the severity. Glucocorticoids are the first-line treatment for most irAEs, with immunosuppressants and biologics mainly used as second-line treatments.
Source: www.acpjournals.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 334Immune-Related Adverse Events of Immune Checkpoint Inhibitors | Annals of Internal Medicine - 3 month(s) ago
Immune-related adverse events (irAEs) are toxicities that arise after the administration of monoclonal antibodies targeting immune checkpoints (immune checkpoint inhibitors [ICIs]) in patients with cancer. They can occur at any time after initiation of ICI treatment, with a broad clinical phenotype that can be organ-specific or systemic. Although most irAEs manifest as mild to moderate signs and symptoms, severe forms of irAEs can lead to irreversible organ failure and have acute life-threatening presentations. Treatment should be tailored to the specific organ involved and the severity. Glucocorticoids are the first-line treatment for most irAEs, with immunosuppressants and biologics mainly used as second-line treatments.
Source: www.acpjournals.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 5Migraine | Annals of Internal Medicine - 1 year(s) ago
Migraine affects about 1 billion people worldwide, and up to 15% of adults in the United States have migraine attacks in any given year. Migraine is associated with substantial adverse socioeconomic and personal effects. It is the second leading cause of years lived with disability worldwide for all ages and the leading cause in women aged 15 to 49 years. Diagnostic uncertainty increases the…
Source: Annals of Internal MedicineCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 27
Monoclonal gammopathy of undetermined significance (MGUS) is of considerable clinical importance to primary care physicians given its high prevalence in the general population. MGUS has a variable but lifelong risk for progression to hematologic cancer, such as multiple myeloma, Waldenström macroglobulinemia, or light-chain amyloidosis. In addition, MGUS has been associated with several…
Source: Annals of Internal MedicineCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2
The previous In the Clinic that addressed preoperative evaluation for noncardiac surgery was published in December 2016. This update reaffirms much of the information in the previous version and provides new information that has accumulated since then. The goal of preoperative assessment is to identify the risk for postoperative complications so health care teams can more fully understand how to…
Source: Annals of Internal MedicineCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 6
The previous In the Clinic that addressed preoperative evaluation for noncardiac surgery was published in December 2016. This update reaffirms much of the information in the previous version and provides new information that has accumulated since then. The goal of preoperative assessment is to identify the risk for postoperative complications so health care teams can more fully understand how to…
Source: Annals of Internal MedicineCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
New #InTheClinic discusses diagnosis and management of immune-related adverse events: https://t.co/z644lL5Tch https://t.co/pVYpbvamKV